WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

<h3>Gainers</h3>
<ul>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 8.5% to $1.08 during Thursday's after-market session. The company's market cap stands at $2.4 million. </li>
<li>WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) shares rose 7.54% to $8.55. The market value of their outstanding shares is at $1.1 billion. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares moved upwards by 6.55% to $2.44. The market value of their outstanding shares is at $8.5 million. </li>
<li>electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) shares increased by 5.96% to $8.0. The company's market cap stands at $59.2 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock rose 5.53% to $3.43. The market value of their outstanding shares is at $310.5 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) shares increased by 5.38% to $4.5. The market value of their outstanding shares is at $75.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) shares fell 18.1% to $2.72 during Thursday's after-market session. The company's market cap stands at $18.4 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares decreased by 12.31% to $0.36. The company's market cap stands at $5.0 million. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares decreased by 11.29% to $2.76. The market value of their outstanding shares is at $241.0 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock fell 8.73% to $0.91. The company's market cap stands at $22.2 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares fell 8.32% to $0.71. The market value of their outstanding shares is at $1.6 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock decreased by 8.22% to $1.34. The company's market cap stands at $49.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADIL

CDXS

CLDI

CTOR

ECOR

INAB

KLTO

NVNO

QTTB

SLRX

12 Health Care Stocks Moving In Thursday's After-Market Session

Analysts' ratings for WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated WAVE Life Sciences and provided 12-month price targets. The average target is $16.0, accompanied by a high estimate of $22.00 and a low estimate of $10.00. Observing a downward trend, the current average is 20.0% lower than the prior average price target of $20.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1750687280_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of WAVE Life Sciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Michael Freeman</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Seedhouse</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to WAVE Life Sciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of WAVE Life Sciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of WAVE Life Sciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of WAVE Life Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WVE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on WAVE Life Sciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know WAVE Life Sciences Better</h2>
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
<h3>Financial Insights: WAVE Life Sciences</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: WAVE Life Sciences's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -26.82%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: WAVE Life Sciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -510.93%, the company may face hurdles in effective cost management.
Return on Equity (ROE): WAVE Life Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -24.59%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): WAVE Life Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -14.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: WAVE Life Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Where WAVE Life Sciences Stands With Analysts

Wedbush analyst Yun Zhong reiterates WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Outperform and maintains $18 price target.

News

Price Target

Reiteration

Wedbush Reiterates Outperform on WAVE Life Sciences, Maintains $18 Price Target

Biotech

General

Wave Life Sciences New Preclinical Data Demonstrate That A Single Dose Of INHBE siRNA Leads To Lower Inflammation Of Adipose Tissue With Strong Suppression Of Pro-inflammatory M1 Macrophages In Visceral Fat In Dio Mice, Highlighting Potential Mechanistic Insights Into The Risk Reduction For Type 2 Diabetes And Coronary Artery Disease Suggested By Human Genetics

Wave Life Sciences Announces Presentation Of Preclinical Data Supporting WVE-007, Its GalNAc-siRNA Designed To Silence INHBE mRNA, An Obesity Target With Strong Evidence From Human Genetics;

Raymond James analyst Michael Freeman assumes WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Outperform rating and announces Price Target of $14.

Initiation

Raymond James Assumes WAVE Life Sciences at Outperform, Announces Price Target of $14

WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.26) by 11.54 percent. This is a 20.83 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $9.18 million which missed the analyst consensus estimate of $12.23 million by 24.96 percent. This is a 26.82 percent decrease over sales of $12.54 million the same period last year.

Earnings

Earnings Misses

WAVE Life Sciences Q1 EPS $(0.29) Misses $(0.26) Estimate, Sales $9.18M Miss $12.23M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-08. Here's a quick overview of what investors should know before the release.
Analysts are estimating that WAVE Life Sciences will report an earnings per share (EPS) of $-0.25.
The market awaits WAVE Life Sciences's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.39, leading to a 5.88% drop in the share price on the subsequent day.
Here's a look at WAVE Life Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.22</td>
<td>-0.28</td>
<td>-0.21</td>
<td>-0.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.17</td>
<td>-0.47</td>
<td>-0.25</td>
<td>-0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-1.0%</td>
<td>-6.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746630201_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of WAVE Life Sciences were trading at $6.41 as of May 06. Over the last 52-week period, shares are up 14.67%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analysts' Perspectives on WAVE Life Sciences</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding WAVE Life Sciences.
Analysts have provided WAVE Life Sciences with 4 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $20.0, suggesting a potential 212.01% upside.
<h3>Comparing Ratings with Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Ocular Therapeutix, Pacira BioSciences and Harrow, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Ocular Therapeutix, with an average 1-year price target of $15.83, suggesting a potential 146.96% upside.</li>
<li>Analysts currently favor an Buy trajectory for Pacira BioSciences, with an average 1-year price target of $44.6, suggesting a potential 595.79% upside.</li>
<li>Analysts currently favor an Buy trajectory for Harrow, with an average 1-year price target of $59.0, suggesting a potential 820.44% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Ocular Therapeutix, Pacira BioSciences and Harrow, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphastar Pharma</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$86.65M</td>
<td>5.20%</td>
</tr>
<tr>
<td>Ocular Therapeutix</td>
<td>Buy</td>
<td>15.41%</td>
<td>$15.85M</td>
<td>-14.50%</td>
</tr>
<tr>
<td>Pacira BioSciences</td>
<td>Buy</td>
<td>3.32%</td>
<td>$147.37M</td>
<td>2.10%</td>
</tr>
<tr>
<td>Harrow</td>
<td>Buy</td>
<td>83.83%</td>
<td>$52.70M</td>
<td>10.62%</td>
</tr>
</tbody>
</table>

Key Takeaway:
WAVE Life Sciences ranks in the middle among its peers for Consensus rating. It is at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity.
<h3>Get to Know WAVE Life Sciences Better</h3>
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
<h3>A Deep Dive into WAVE Life Sciences's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining WAVE Life Sciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 188.23% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: WAVE Life Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 34.93%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): WAVE Life Sciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 16.66%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): WAVE Life Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of 8.23%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.12, WAVE Life Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/WVE/earnings">To track all earnings releases for WAVE Life Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WAVE Life Sciences Earnings Preview

WIIM

BHVN

CAPR

CRSP

MARA

NVAX

SLDB

SRPT

TSHA

XNCR

Shares of vaccine and gene therapy stocks are trading lower after FDA Commissioner Marty Makary reportedly named Vinay Prasad as director of the Center for Biologics and Research.

<a href="https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics" title="https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics">https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics</a>

DSGN

MRNA

PTCT

'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law

4 analysts have expressed a variety of opinions on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $20.0, a high estimate of $26.00, and a low estimate of $10.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.09%. 
<img src="https://www.benzinga.com/files/images/story/2025/1745964024_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of WAVE Life Sciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Seedhouse</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Roger Song</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$26.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to WAVE Life Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of WAVE Life Sciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for WAVE Life Sciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into WAVE Life Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WVE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on WAVE Life Sciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About WAVE Life Sciences</h2>
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
<h3>Breaking Down WAVE Life Sciences's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining WAVE Life Sciences's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 188.23% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: WAVE Life Sciences's net margin is impressive, surpassing industry averages. With a net margin of 34.93%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): WAVE Life Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.66% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): WAVE Life Sciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 8.23%, the company showcases efficient use of assets and strong financial health.
Debt Management: WAVE Life Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: WAVE Life Sciences In The Eyes Of 4 Experts

Wave Life Sciences shares are trading higher after Cantor Fitzgerald initiated coverage with an Overweight rating and $10 price target.

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Overweight rating and announces Price Target of $10.

Cantor Fitzgerald Initiates Coverage On WAVE Life Sciences with Overweight Rating, Announces Price Target of $10

HC Wainwright &amp; Co. analyst Andrew Fein reiterates WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and maintains $22 price target.

HC Wainwright & Co. Reiterates Buy on WAVE Life Sciences, Maintains $22 Price Target

Wave Life Sciences Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) released data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon-skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">to exon 53 skipping</a>.
DMD is the most common hereditary neuromuscular disease. Mutations in the&nbsp;dystrophin&nbsp;gene lead to progressive muscle fiber <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44490973/wave-life-sciences-announces-positive-data-from-forward-53-clinical-trial-in-dmd-including-signifi" rel="noreferrer noopener">degeneration and weakness</a>.
The company on Wednesday said FORWARD-53 achieved all trial goals, demonstrating sustained exon skipping, muscle concentrations, and dystrophin restoration through 48 weeks and a 61-day tissue half-life that supports monthly dosing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41359843/wave-life-sciences-reveals-rna-editing-breakthrough-reports-first-ever-clinical-proof-of-mechanis" rel="noreferrer noopener">Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans</a>
WVE-N531 continues to be safe and well-tolerated.
Additionally, the company said the data demonstrate substantial decreases in inflammation and necrosis, a statistically significant reversal of muscle fibrosis (28.6% reduction between weeks 24 and 48), and a transition from muscle regeneration to maturation.
A 50% decline in creatine kinase (CK) and decreases in IL-6 and MCP-1 were also observed.
Time-to-Rise (TTR) data demonstrate a statistically significant and clinically meaningful 3.8-second improvement versus natural history.
Additional functional benefits were observed on the North Star Ambulatory Assessment (NSAA) compared to natural history and in-hand grip strength compared to baseline.
On Wednesday, Wave also announced that it met with the U.S. Food and Drug Administration (FDA) on WVE-N531 to discuss its interim 24-week data and initial plans for the confirmatory trial.
Wave intends to file a New Drug Application in 2026 for accelerated approval of WVE-N531.
WVE-N531, as well as Wave&#8217;s programs for exons 52, 51, 45, and 44, collectively could address around 40% of the DMD population and represent over $2.4 billion in total market opportunity in the United States alone.
Wave expects to submit multiple clinical trial applications for other exon-skipping programs in 2026.
Price Action: WVE stock is up 14.9% at $10.85 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44492590/alibaba-and-bmw-team-up-to-bring-ai-powered-smart-assistant-to-next-gen-cars-in-china" target="_blank" rel="noreferrer noopener">Alibaba, BMW Team Up To Bring AI-Powered Smart Assistant In Next-Gen China Cars</a></li>
</ul>
Photo: Shutterstock

Health Care

Trading Ideas

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year

Wave Life Sciences shares are trading higher after the company announced its Phase 2 DMD trial results.

Wave Life Sciences Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. The analysis was conducted after 48 weeks of treatment with 10 mg/kg WVE-N531 dosed every two weeks (Q2W).
FORWARD-53 achieved all trial goals, demonstrating sustained and industry-leading exon skipping, muscle concentrations and dystrophin restoration through 48 weeks and a 61-day tissue half-life that supports monthly dosing. WVE-N531 continues to be safe and well-tolerated.
Additionally, the data demonstrate substantial decreases in inflammation and necrosis, a statistically significant reversal of muscle fibrosis (28.6% reduction between week 24 to 48; p&lt;0.01), and a transition from regeneration to maturation of muscle. A 50% decline (&lt;0.001) in creatine kinase (CK), as well as decreases in IL-6 and MCP-1, were also observed. Time-to-Rise (TTR) data demonstrate a statistically significant and clinically meaningful 3.8-second improvement versus natural history (p&lt;0.05), which is the largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks. Additional functional benefits were observed on the North Star Ambulatory Assessment (NSAA) versus natural history, and in hand grip strength versus baseline.

Wave Life Sciences Reports Phase 2 DMD Trial Results With Dystrophin Restoration

Wave Life Sciences shares are trading higher after the company reported better-than-expected Q4 financial results.

Press Releases

Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

Management

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

Comments

WAVE Life Sciences

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL